Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935135 | 0.97 | HRH3 (0.54) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL14935322 | 0.93 | HRH3 (0.56) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL16567294 | 0.88 | HRH3 (0.60) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL22468169 | 0.86 | HRH3 (0.49) | HRH3NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL16566696 | 0.85 | HRH3 (0.56) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL18315883 | 0.83 | HRH3 (0.47) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL16566810 | 0.83 | HRH3 (0.58) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL16566761 | 0.80 | HRH3 (0.54) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL7811609 | 0.77 | NPC1 (0.78) | HRH3NPC1RAB9AFAAHTP53 | |
| SCHEMBL3039278 | 0.76 | HRH3 (0.71) | HRH3NPC1RAB9AFAAHTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315509-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | DOMAIN PARTNERS VIII, L.P. | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | HRH3 21/4885NPC1 1157/4885RAB9A 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.